Assessment of the recoverability
of investments in subsidiaries' shares
The net value of investments in subsidiaries as
at 31 December 2023 was PLN
4 807 million,
which represents 9,8
%
of the Company’s total
assets, including:
-
investments in shares in Future 1 Sp. z o. o.
amounted to PLN 2,852 million
,
- investment in shares in KGHM Metraco S.A.,
amounted to PLN 421 million,
-
remaining investment in stock and shares of
other entities - PLN
1 534 million.
Investments in subsidiaries are carried at
acquisition cost less impairment losses.
Accounting policies and disclosures regarding
investments in subsidiaries are disclosed in
note 6.1 to the annual separate financial
statements
.
As at December 31, 2023, the Company
identified triggers for impairment in relation to
the following investments in subsidiaries:
a) investment in shares in Future 1 Sp. z o. o.,
b)
investment
in
shares
in
KGHM
Metraco
S.A.,
c) investment in shares in Zagłębie Lubin S.A.
As
a
result
of
the
tests,
in
the
separate
financial
statements:
-
the
recoverable
value
of
the
investment
in
shares
in
the
company
Future
1
Sp.
z
o.
o.
was
determined
at
the
level
of
PLN
2,852
million,
which
was
higher
than
the
carrying
amount
of
this
asset,
which
was
the
basis
for
reversing
the
Our testing procedures included in particular
:
●
verification of compliance of the adopted
valuation principle with applicable accounting
standards,
●
understanding and assessing the process of
identification by the Management Board of
triggers for occurrence or reversal of
impairment of investments in subsidiaries,
●
understanding and assessing the correctness
of the methods used to conduct impairment
tests in accordance with the relevant financial
reporting standards,
●
checking mathematical correctness and
methodological consistency (using internal
valuation experts) of the recoverable amount
valuation models prepared by the Company's
Management Board,
●
ritical assessment of the assumptions
adopted by the Company's Management
Board and estimates made to determine the
recoverable amount, including, among others:
○
the projection period of future cash
flows based on the approved budgets
for companies for which an
impairment test was performed and
the level of revenues, operating
margin and future investment
expenditures assumed therein,
○
discount rate used (based on the
weighted average cost of capital),
○
residual value, including the residual
growth rate after the forecast period.